Xilio Therapeutics Inc (XLO) News & EventsXLOXilio Therapeutics Inc

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Xilio Therapeutics announced the appointment of Ben Harshbarger as chief legal officer. recently, he served as chief legal officer at Astria Therapeutics, Inc. until its acquisition.

Xilio Therapeutics Files $250M Mixed Securities Shelf

Xilio Therapeutics files $250M mixed securities shelf

Xilio Therapeutics Announces New Data for XTX601

Xilio Therapeutics announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2, at the American Association for Cancer Research Annual Meeting, taking place from April 17-22 in San Diego, California. "The data to be presented at AACR underscore the significant potential of our clinically-validated masking technology to address the central challenge that has limited the advancement of T cell engagers in solid tumors - namely, the inability to achieve meaningful anti-tumor activity without inducing severe systemic toxicities," said Uli Bialucha, Chief Scientific Officer of Xilio Therapeutics. "XTX601 has demonstrated a promising preclinical profile, including potent tumor cell killing across multiple CLDN18.2-expressing tumor models and a favorable tolerability profile in non-human primates, supporting its potential to achieve a wide therapeutic index. Importantly, our modular architecture for masked T cell engagers provides flexibility to rapidly evaluate multiple designs in parallel, including masking of the CLDN18.2 binding domain and/or the addition of a co-stimulatory domain, which enables us to seek to optimize the molecule for the best possible clinical profile."